Exane Derivatives’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Exane Derivatives’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-21,333	Closed	-$157K	–	1087
2021 Q2	$157K	Hold	21,333	–	–	0.04%	460
2021 Q1	$173K	Buy	+21,333	New	+$232K	0.05%	324

Other funds holding KLDO

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Exane Derivatives's KLDO Position: Q3 2021 in Review

Exane Derivatives sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q3 2021, closing a stake of 21,333 shares — an estimated $157K sold.

Exane Derivatives first reported a position in KLDO in Q1 2021 and held it in 2 quarters. The position peaked at $173K in Q1 2021. 71 funds tracked by Wall St. Rank hold KLDO as of Q3 2021.

Exane Derivatives reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Exane Derivatives sold 21,333 Kaleido Biosciences, Inc. Common Stock shares in Q3 2021, an estimated $157K.
Exane Derivatives first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
Exane Derivatives's Kaleido Biosciences, Inc. Common Stock position peaked at $173K in Q1 2021.
71 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q3 2021.

Based on Exane Derivatives's 13F filing for Q3 2021, filed 26 Oct 2021.